492 related articles for article (PubMed ID: 29679756)
21. Association of a novel in-frame deletion mutation of the MYH9 gene with end-stage renal failure: case report and review of the literature.
Ishida M; Mori Y; Ota N; Inaba T; Kunishima S
Clin Nephrol; 2013 Sep; 80(3):218-22. PubMed ID: 22541678
[TBL] [Abstract][Full Text] [Related]
22. MYH9-related disease mutations cause abnormal red blood cell morphology through increased myosin-actin binding at the membrane.
Smith AS; Pal K; Nowak RB; Demenko A; Zaninetti C; Da Costa L; Favier R; Pecci A; Fowler VM
Am J Hematol; 2019 Jun; 94(6):667-677. PubMed ID: 30916803
[TBL] [Abstract][Full Text] [Related]
23. Preoperative use of platelets in a 6-year-old with acute appendicitis and a myosin heavy chain 9-related disorder: a case report and review of literature.
Eichel Y; Tormos LM; Squires JE
Transfusion; 2016 Feb; 56(2):349-53. PubMed ID: 26446054
[TBL] [Abstract][Full Text] [Related]
24. A Japanese pedigree with a p.A95V mutation in the MYH9 gene demonstrates inherited macrothrombocytopenia without Alport manifestations.
Yokoi S; Kunishima S; Takahashi Y; Morishita M; Kojima S
Ann Hematol; 2016 Apr; 95(5):831-3. PubMed ID: 26861218
[No Abstract] [Full Text] [Related]
25. Somatic mosaicism in MYH9 disorders: the need to carefully evaluate apparently healthy parents.
Kunishima S; Kitamura K; Matsumoto T; Sekine T; Saito H
Br J Haematol; 2014 Jun; 165(6):885-7. PubMed ID: 24611568
[No Abstract] [Full Text] [Related]
26. [Autosomal dominant macrothrombocytopenia with leukocyte inclusion bodies and MYH9 disorders].
Kunishima S
Rinsho Byori; 2009 Apr; 57(4):365-70. PubMed ID: 19489439
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and treatment of
Rabbolini DJ; Chun Y; Latimer M; Kunishima S; Fixter K; Valecha B; Tan P; Chew LP; Kile BT; Burt R; Radhakrishnan K; Bird R; Ockelford P; Gabrielli S; Chen Q; Stevenson WS; Ward CM; Morel-Kopp MC
Platelets; 2018 Dec; 29(8):793-800. PubMed ID: 29090586
[No Abstract] [Full Text] [Related]
28. Renal manifestations of patients with MYH9-related disorders.
Han KH; Lee H; Kang HG; Moon KC; Lee JH; Park YS; Ha IS; Ahn HS; Choi Y; Cheong HI
Pediatr Nephrol; 2011 Apr; 26(4):549-55. PubMed ID: 21210153
[TBL] [Abstract][Full Text] [Related]
29. Advances in the understanding of MYH9 disorders.
Kunishima S; Saito H
Curr Opin Hematol; 2010 Sep; 17(5):405-10. PubMed ID: 20601875
[TBL] [Abstract][Full Text] [Related]
30. Avatrombopag improves thrombocytopenia in MYH9-related disorder following eltrombopag treatment failure.
Arif AR; Zhao M; Chen W; Xue M; Luo S; Wang Y
Platelets; 2022 Nov; 33(8):1307-1311. PubMed ID: 35791514
[TBL] [Abstract][Full Text] [Related]
31. CKD in MYH9-related disorders.
Singh N; Nainani N; Arora P; Venuto RC
Am J Kidney Dis; 2009 Oct; 54(4):732-40. PubMed ID: 19726116
[TBL] [Abstract][Full Text] [Related]
32. Absence of hearing loss in a mouse model for DFNA17 and MYH9-related disease: the use of public gene-targeted ES cell resources.
Parker LL; Gao J; Zuo J
Brain Res; 2006 May; 1091(1):235-42. PubMed ID: 16630581
[TBL] [Abstract][Full Text] [Related]
33. A G to C transversion at the last nucleotide of exon 25 of the MYH9 gene results in a missense mutation rather than in a splicing defect.
Vettore S; De Rocco D; Gerber B; Scandellari R; Bianco AM; Balduini CL; Pecci A; Fabris F; Savoia A
Eur J Med Genet; 2010; 53(5):256-60. PubMed ID: 20603234
[TBL] [Abstract][Full Text] [Related]
34. [Hereditary sensorineural hearing impairment and macrothrombocytopenia: a rare MYH9 gene mutation].
Böttcher A; Knecht R; Busch CJ; Lörincz BB; Dalchow CV
HNO; 2013 Feb; 61(2):159-60, 162-5. PubMed ID: 23223919
[TBL] [Abstract][Full Text] [Related]
35. MYH9-related disease: five novel mutations expanding the spectrum of causative mutations and confirming genotype/phenotype correlations.
De Rocco D; Zieger B; Platokouki H; Heller PG; Pastore A; Bottega R; Noris P; Barozzi S; Glembotsky AC; Pergantou H; Balduini CL; Savoia A; Pecci A
Eur J Med Genet; 2013 Jan; 56(1):7-12. PubMed ID: 23123319
[TBL] [Abstract][Full Text] [Related]
36. Signaling via the angiotensin-converting enzyme results in the phosphorylation of the nonmuscle myosin heavy chain IIA.
Kohlstedt K; Kellner R; Busse R; Fleming I
Mol Pharmacol; 2006 Jan; 69(1):19-26. PubMed ID: 16186248
[TBL] [Abstract][Full Text] [Related]
37. Role for formin-like 1-dependent acto-myosin assembly in lipid droplet dynamics and lipid storage.
Pfisterer SG; Gateva G; Horvath P; Pirhonen J; Salo VT; Karhinen L; Varjosalo M; Ryhänen SJ; Lappalainen P; Ikonen E
Nat Commun; 2017 Mar; 8():14858. PubMed ID: 28361956
[TBL] [Abstract][Full Text] [Related]
38. MYH9 gene mutations associated with bleeding.
Savoia A; De Rocco D; Pecci A
Platelets; 2017 May; 28(3):312-315. PubMed ID: 28368695
[No Abstract] [Full Text] [Related]
39. Congenital thrombocytopenia with nephritis - The first case of MYH9 related disorder in Serbia.
Kuzmanović M; Kunishima S; Putnik J; Stajić N; Paripović A; Bogdanović R
Vojnosanit Pregl; 2014 Apr; 71(4):395-8. PubMed ID: 24783421
[TBL] [Abstract][Full Text] [Related]
40. Nonmuscle myosin IIA is associated with poor prognosis of esophageal squamous cancer.
Xia ZK; Yuan YC; Yin N; Yin BL; Tan ZP; Hu YR
Dis Esophagus; 2012 Jul; 25(5):427-36. PubMed ID: 21951916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
